Registry Platform Myelofibrosis and Anemia

Launched by IOMEDICO AG · May 9, 2025

Keywords

ClinConnect Summary

The "Registry Platform Myelofibrosis and Anemia" trial is a study aimed at gathering important information about patients who have myelofibrosis, a type of blood cancer, and anemia, a condition where you don't have enough healthy red blood cells. The goal is to create a national registry in Germany that tracks details about patients' health, the treatments they receive, and their experiences with the disease over time. This information will help doctors understand how to better treat myelofibrosis and improve care for patients.

To participate in this trial, you need to have a confirmed diagnosis of primary or secondary myelofibrosis and be diagnosed with anemia. You should also be starting your first or any follow-up treatment for myelofibrosis. If you join, you’ll provide consent and participate in assessments about your health during the study. It’s important to know that this trial is not currently recruiting participants, so you would need to wait until it starts. Overall, this study aims to enhance knowledge and treatment options for those affected by these conditions.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Confirmed diagnosis of primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF) (Note: diagnosis according to WHO-2017, ICC-2022 or WHO-2022 or IWG-MRT criteria, respectively).
• • Diagnosis of anemia at the time of enrollment as per individual, clinical assessment by the local physician.
• • Start of first or subsequent systemic treatment for MF.
• • Informed consent and registration for the GSG-MPN Bioregistry.
• • Willingness and capability to participate in PRO assessment.
• • Signed and dated informed consent form for RHODOLITE at the latest six weeks after start of the respective systemic MF treatment.
• Exclusion Criteria:
• • No systemic therapy for diagnosed primary or secondary MF.
• • Planned allogenic stem cell transplantation (allo-SCT) or active participation in an interventional clinical trial.